glp 1 coverage 2025 Poll: in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford GLP-1 drugs , like most

Rare sugars suppress fat accumulation in mice

It is ideal for researchers starting at low doses or those who want to minimize waste during short protocols

GLP-1RAs, originally developed for glycemic control, have shown neuroprotective properties in many preclinical studies

A 2025 study in the American Journal of Ophthalmology did not find a significant increase in NAION or ischemic optic neuropathy risk in patients taking semaglutide or GLP-1 medications compared with diabetes or high-BMI control groups

Similarly, other subgroup analyses have explored the role of baseline cardiovascular risk as a potential effect modifier regarding the effect of treatment on MACE, HHF or kidney outcomes

8-year trends in obesity, type 2 diabetes, and glucagon-like peptide-1 (GLP-1) use in patients with obstructive sleep apnea